Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 856 AL 870

Serotonin in depression and Alzheimer's disease: Focus on SSRI's beneficial effects

Tahiri J, Mian M, Aftan F, Habbal S, Salehi F, Reddy PH, Reddy AP.

Ageing Res Rev. 2024 Nov;101:102537. doi: 10.1016/j.arr.2024.102537. Epub 2024 Oct 9.

Exploring nanoparticular platform in delivery of repurposed drug for Alzheimer's disease: current approaches and future perspectives

Chakraborty S, Vishwas S, Harish V, Gupta G, Paudel KR, Dhanasekaran M, Goh BH, Zacconi F, de Jesus Andreoli Pinto T, Kumbhar P, Disouza J, Dua K, Singh SK.

Expert Opin Drug Deliv. 2024 Dec;21(12):1771-1792. doi: 10.1080/17425247.2024.2414768. Epub 2024 Oct 13.

Safety, tolerability, and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer's disease (ILiAD) study: a pilot, double-blind placebo-controlled crossover trial

Sen A, Toniolo S, Tai XY, Akinola M, Symmonds M, Mura S, Galloway J, Hallam A, Chan JYC, Koychev I, Butler C, Geddes J, Jones GD, Tabi Y, Maio R, Frangou E, Love S, Thompson S, Van Der Putt R, Manohar SG, McShane R, Husain M.

Epilepsia Open. 2024 Dec;9(6):2353-2364. doi: 10.1002/epi4.13070. Epub 2024 Oct 14.

Exploring the multiple therapeutic mechanisms and challenges of mesenchymal stem cell-derived exosomes in Alzheimer's disease

Ma YN, Hu X, Karako K, Song P, Tang W, Xia Y.

Biosci Trends. 2024 Nov 15;18(5):413-430. doi: 10.5582/bst.2024.01306. Epub 2024 Oct 11.

Anti-amyloid β Antibody Therapies for Alzheimer's Disease: Association between the Target of Amyloid β Aggregates and the Clinical Efficacy of Anti-amyloid β Antibody

Noguchi-Shinohara M, Ono K.

Intern Med. 2026 Jan 1;65(1):67-70. doi: 10.2169/internalmedicine.4604-24. Epub 2024 Oct 11.

Exploring the Benzazoles Derivatives as Pharmacophores for AChE, BACE1, and as Anti-Aβ Aggregation to Find Multitarget Compounds against Alzheimer's Disease

Rosales Hernández MC, Olvera-Valdez M, Velazquez Toledano J, Mendieta Wejebe JE, Fragoso Morales LG, Cruz A.

Molecules. 2024 Oct 9;29(19):4780. doi: 10.3390/molecules29194780.

Intrathecal Immunoselective Nanopheresis for Alzheimer's Disease: What and How? Why and When?

Menendez-Gonzalez M.

Int J Mol Sci. 2024 Oct 2;25(19):10632. doi: 10.3390/ijms251910632.

Melatonin in Alzheimer's Disease: Literature Review and Therapeutic Trials

Steinbach MJ, Denburg NL.

J Alzheimers Dis. 2024;101(s1):S193-S204. doi: 10.3233/JAD-230760.

CT1812, a Small Molecule Sigma-2 Receptor Antagonist for Alzheimer's Disease Treatment: A Systematic Review of Available Clinical Data

Thitilertdecha P, Brimson JM.

J Alzheimers Dis. 2024;101(s1):S115-S128. doi: 10.3233/JAD-230994.

CMS121, a Novel Drug Candidate for the Treatment of Alzheimer's Disease and Age-Related Dementia

Currais A, Raschke W, Maher P.

J Alzheimers Dis. 2024;101(s1):S179-S192. doi: 10.3233/JAD-231062.

Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer's Disease

Feldman HH, Messer K, Qiu Y, Sabbagh M, Galasko D, Turner RS, Lopez O, Smith A, Durant J, Lupo JL, Revta C, Balasubramanian A, Kuehn-Wache K, Wassmann T, Schell-Mader S, Jacobs DM, Salmon DP, Léger G, DeMarco ML, Weber F; ADCS VIVA-MIND Study Group.

J Alzheimers Dis. 2024;101(s1):S79-S93. doi: 10.3233/JAD-231126.

BACE Inhibitor Clinical Trials for Alzheimer's Disease

Watkins EA, Vassar R.

J Alzheimers Dis. 2024;101(s1):S41-S52. doi: 10.3233/JAD-231258.

Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach

Alghamdi M, Braidy N.

J Alzheimers Dis. 2024;101(s1):S467-S477. doi: 10.3233/JAD-231277.

Pharmacodynamic and Clinical Effects of Ginkgo Biloba Extract EGb 761 and Its Phytochemical Components in Alzheimer's Disease

Morató X, Tartari JP, Pytel V, Boada M.

J Alzheimers Dis. 2024;101(s1):S285-S298. doi: 10.3233/JAD-231372.

Alzheimer's Disease and (Phyto) Estrogen Treatment: Modification of Effects by Age, Type of Treatment, and Duration of Use

Kuck MJ, Begde A, Hawkins K, Hogervorst E.

J Alzheimers Dis. 2024;101(s1):S217-S234. doi: 10.3233/JAD-231415.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias